|Classification Name:||Extracellular matrix protein|
|Manufacturer:||Mölnlycke Health Care|
Xelma consists of a viscous solution of extracellular matrix proteins (amelogenins) in propylene-glycol alginate. Xelma provides a temporary extracellular matrix for cell attachment which creates favourable conditions for wound healing by restoring vital cell functions including proliferation, migration and the production of growth factors and natural essential extracellular matrix proteins.
Restoration of the cellular and biochemical balance is thereby facilitated in the hard-to-heal wound, which promotes granulation tissue formation and normal wound healing.
Xelma is recommended for the treatment of hard-to-heal wounds such as venous leg ulcers which have failed to respond to standard therapies.
Xelma should not be used on clinically infected wounds or in patients with known sensitivity to the product components.
The wound should first be measured, then if clinically indicated, debrided or cleansed.
Once the wound has been prepared, the rubber cap is removed from the syringe and the applicator attached to facilitate application of the viscous solution. A thin layer of Xelma matrix protein is then applied to the wound using the graduations on the syringe to help deliver the correct amount for the size of the wound. A secondary dressing such as Mepitel or one of the Mepilex range is then applied as appropriate.
Xelma may be reapplied weekly. Depending upon the amount of exdudate present, the secondary dressing may be changed more frequently than this.
If after six weeks no significant improvement is observed, both the wound and treatment should be reassessed.
Xelma should be stored in a fridge.
Xelma is presented in a disposable syringe completed with silicone applicator.
|Revision Author||Dr S. Thomas|
This datacard has been prepared from data provided by the manufacturer and/or from published literature.